Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Chugai Pharmaceutical Co ( (JP:4519) ) has provided an announcement.
F. Hoffmann-La Roche Ltd., the Swiss-headquartered parent company of Chugai Pharmaceutical, has announced its financial results for fiscal 2025, covering the period from January 1 to December 31, 2025. Chugai’s performance for the same period is consolidated within the Roche Group’s reported results, underscoring Chugai’s role as a majority-owned subsidiary whose financial and operational outcomes are reflected in the parent group’s disclosures to investors.
The most recent analyst rating on (JP:4519) stock is a Buy with a Yen9900.00 price target. To see the full list of analyst forecasts on Chugai Pharmaceutical Co stock, see the JP:4519 Stock Forecast page.
More about Chugai Pharmaceutical Co
Chugai Pharmaceutical Co., Ltd. is a Japan-based pharmaceutical company listed on the Prime Market of the Tokyo Stock Exchange, engaged in the research, development, and commercialization of prescription medicines. It operates within the Roche Group, with Roche Holding Ltd., based in Switzerland, holding a majority of Chugai’s issued shares and voting rights, positioning Chugai as a key contributor to Roche’s global pharmaceutical business.
Average Trading Volume: 2,310,532
Technical Sentiment Signal: Buy
Current Market Cap: Yen14293.6B
Learn more about 4519 stock on TipRanks’ Stock Analysis page.